Effect of the Nasal Gel "Nascum®-Plus" on Allergic Symptoms
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess if a physical barrier, created by the nasal gel Nascum®-
Plus, is able to prevent or minimize the induction of nasal symptoms during allergen
challenge in the Fraunhofer Allergen Challenge Chamber (ACC). Furthermore, the effect on
soluble and cellular inflammatory markers induced by the allergic reaction will be assessed.
Nascum®-Plus contains no active pharmaceutical ingredient, only monographed pharmaceutical
excipients.
Phase:
N/A
Details
Lead Sponsor:
Fraunhofer-Institute of Toxicology and Experimental Medicine